The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Nigel J. Waters(Epizyme (United States)), Roy M. Pollock(C4 Therapeutics (United States)), Stephen J. Blakemore(Epizyme (United States)), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Andrei V. Krivtsov(Memorial Sloan Kettering Cancer Center), Raoul Tibes(BioNTech (Germany)), Jessica K. Altman(Northwestern University), Eric Hedrick(Florida Hospital Cancer Institute), Alicia Clawson(Epizyme (United States)), A. Benjamin Suttle(Epizyme (United States)), Bob Löwenberg(Unknown), Michael R. Savona(Vanderbilt University), Jesús G. Berdeja(Tennessee Oncology), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), David A. Rizzieri(Duke University), Mojca Jongen-Lavrenic(Erasmus MC), Blythe Thomson(Epizyme (United States)), Scott R. Daigle(Epizyme (United States)), Jorge DiMartino
Cited by 457
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k